The Bottom Line

If you have been diagnosed with melanoma or a suspicious mole, the ABCDE rule can help you understand what your doctors are evaluating and why. The five features—Asymmetry, Border irregularity, Color variation, Diameter, and Evolution—are the clinical signs that prompted biopsy and diagnosis. Understanding these signs, how staging works, and what treatment looks like at each stage can help you feel more informed and less anxious as you move forward.

What Is the ABCDE Rule and Why Does It Matter to You?

The ABCDE rule is the set of clinical warning signs that dermatologists use to identify moles that need to be biopsied for melanoma. If you have received a melanoma diagnosis, there is a good chance one or more of these features—Asymmetry, Border irregularity, Color variation, Diameter greater than 6 mm, or Evolution—was what prompted your dermatologist to recommend a biopsy in the first place.

Understanding these criteria helps you see the logic behind your care. It also helps you stay engaged in your own monitoring going forward, because people who understand what to look for catch recurrences or new melanomas earlier.

Revisiting the Five Warning Signs

Asymmetry

A melanoma grows in a disorganized, uneven pattern, so the two halves of the lesion look different from each other. Benign moles grow symmetrically because their cells divide in an orderly way. When a mole becomes asymmetric—when folding it in your mind would produce two mismatched halves—that is a signal worth investigating.

Border Irregularity

Normal moles have smooth, clearly defined edges. Melanoma borders tend to be ragged, notched, or blurry because the cancer cells at the edge of the tumor are infiltrating the surrounding skin unevenly. Some areas advance faster than others, creating an irregular perimeter.

Color Variation

A single mole containing multiple colors—black, dark brown, lighter brown, tan, red, white, or blue—is a major warning sign. The different colors reflect different things happening within the tumor: areas rich in melanin (very dark), areas of active inflammation (reddish), and areas where the immune system has attacked cancer cells and left depigmented (white or pale) scars.

Diameter

The classic teaching is that melanomas are often larger than 6 mm—about the size of a pencil eraser—when diagnosed. However, about 25–30% of melanomas are smaller than this at diagnosis. Diameter is one factor in the picture, not the whole picture. Very small lesions are not automatically safe if they show other warning signs or are clearly evolving.

Evolution

Perhaps the most telling sign of all: a mole that changes. Benign moles stay stable for years or even decades. A mole that has grown, darkened, changed shape, developed new colors, started itching, or begun to bleed in recent months is a mole that is doing something—and that something needs to be investigated. Research shows that evolution is one of the most specific ABCDE features, correctly identifying melanoma in 95–98% of cases where it is clearly present.

What Happens After the ABCDE Warning Signs Are Noticed

Dermoscopy

When your dermatologist sees an ABCDE-positive mole, the next step is dermoscopy—a handheld magnifying instrument with polarized light that reveals structures beneath the skin surface. These include pigment patterns, blood vessel arrangements, and microscopic features that either raise or lower suspicion. Studies show dermoscopy improves diagnostic accuracy from about 60–70% (with naked-eye exam) to 90–95% in expert hands.

Biopsy and Pathology

If dermoscopy supports the concern, a biopsy is performed—for melanoma, preferably an excisional biopsy that removes the entire lesion. The pathologist then measures several critical features:

  • Breslow thickness: How deep the melanoma has grown into the skin. This is the single most important prognostic factor.
  • Ulceration: Whether the surface of the tumor has broken down. Ulceration worsens prognosis.
  • Mitotic rate: How quickly cancer cells are dividing. Higher rates indicate more aggressive behavior.
  • Clark level: Which layer of skin the melanoma has reached.
  • Margin status: Whether cancer cells are present at the edges of the removed tissue.

Understanding Your Stage

Staging uses the pathology results plus information about your lymph nodes and other organs to assign a stage from 0 to IV. Your stage determines prognosis and treatment:

  • Stage 0 (in situ): Cancer cells are in the surface layer only; essentially 100% curable with surgery
  • Stage I: Thin melanoma, no spread; 92–97% five-year survival
  • Stage II: Thicker or ulcerated melanoma, no spread; 53–81% five-year survival depending on substage
  • Stage III: Lymph node involvement; 40–78% five-year survival—wide range depending on how many nodes are involved
  • Stage IV: Distant spread; survival varies widely (7–50%) but has improved dramatically with modern immunotherapy and targeted therapy

Treatment Based on Stage

Stage 0 and Stage I

Wide local excision—surgical removal of the melanoma with a margin of healthy tissue—is the primary and often only treatment needed. Margin widths depend on thickness:

  • In situ: 0.5–1 cm
  • Up to 1 mm thick: 1 cm
  • 1–2 mm thick: 1–2 cm

For many Stage I patients, this one surgery is curative. No chemotherapy, radiation, or immunotherapy is typically needed.

Stage II and IIB/IIC

Wider excision (up to 2 cm margin) plus sentinel lymph node biopsy to check whether any cancer has traveled to nearby lymph nodes. If nodes are clear, surgery may be all that is needed, though some Stage IIB/IIC patients may be offered adjuvant immunotherapy trials.

Stage III

Surgery plus adjuvant immunotherapy. Both pembrolizumab (Keytruda) and nivolumab (Opdivo) are approved for adjuvant use after Stage III melanoma surgery and significantly reduce the chance of recurrence. If your tumor has a BRAF mutation, adjuvant targeted therapy (dabrafenib + trametinib) is another option.

Stage IV

Checkpoint inhibitor immunotherapy is the backbone of treatment. Combination therapy (nivolumab + ipilimumab) achieves response rates of 50–60%. For BRAF-mutated tumors, BRAF/MEK inhibitor therapy (dabrafenib + trametinib) can produce rapid responses. Some patients achieve long-term remission even at Stage IV with modern treatment.

Monitoring After Treatment

After your initial treatment, regular follow-up is essential. Melanoma can recur, and new primary melanomas can develop in people who have had one. Typical follow-up schedules:

  • Every 3–6 months for the first 2–3 years
  • Every 6–12 months for years 3–5
  • Annually thereafter (for life, in many guidelines)

At each visit, your dermatologist will perform a full-body skin exam. For Stage III–IV patients, imaging (CT scans or PET scans) may be part of routine monitoring.

When to Contact Your Doctor Between Visits

  • A new mole appears or an existing one changes
  • You notice a lump under the skin (which could represent a lymph node or subcutaneous metastasis)
  • You develop unexplained weight loss, fatigue, or pain
  • The biopsy or surgical site changes appearance or fails to heal
  • Any symptom that concerns you—do not wait for your next scheduled visit

Frequently Asked Questions

I had my melanoma removed. Am I cured?

For Stage I and many Stage II melanomas, surgery with clear margins achieves cure for the majority of patients. Your dermatologist will discuss your specific recurrence risk based on Breslow thickness, ulceration status, and other pathology findings. Even with a high cure rate, ongoing monitoring is important because a small percentage of melanomas recur and because people who have had one melanoma are at elevated risk for new primary melanomas.

How do I know if my melanoma is likely to spread?

The two most powerful predictors are Breslow thickness (thicker = higher risk) and whether cancer has reached your lymph nodes. Ulceration and high mitotic rate also increase risk. Your pathology report will include these details. Your dermatologist will interpret them in the context of your overall picture and explain what they mean for your follow-up and treatment plan.

Should I be worried about family members getting melanoma too?

Having a first-degree relative (parent, sibling, child) with melanoma increases your family members’ risk compared to the general population. If you have two or more first-degree relatives with melanoma, that risk is substantially higher and genetic counseling may be warranted. Advise your family members to start performing monthly skin self-exams using the ABCDE rule and to see a dermatologist for a baseline full-body skin exam.

Does having had melanoma mean all my moles are dangerous?

No. Having had melanoma means you are at higher risk of developing another new primary melanoma compared with the general population, but it does not mean all your existing moles will become cancer. The ABCDE rule continues to be your monitoring guide—look for moles that are changing or have multiple warning signs. Your dermatologist may photograph your moles at each visit to track changes over time.

References

  1. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987;116(3):303-310.
  2. Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCDE criteria. JAMA. 2004;292(22):2771-2776.
  3. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159-165.
  4. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the AJCC 8th edition staging system. CA Cancer J Clin. 2017;67(6):472-492.
  5. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131-149.
  6. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  7. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
  8. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma. JAMA. 2003;289(24):3226-3229.

Trusted Resources

Always consult a board-certified dermatologist for personalized advice about your diagnosis and follow-up care. This article is for educational purposes and does not replace individualized medical advice.